Azafaros B.V., a Leiden, The Netherlands-based rare metabolic disorders pipeline developer, closed a Series A financing round of €25m (approximately USD$28m).
The round was led by Forbion with participation from BioMedPartners and founding investor BioGeneration Ventures.
The company holds an exclusive license from LU and Amsterdam UMC to a library of novel patented compounds discovered by internationally recognized experts in the field, Professor Hans Aerts, PhD, Professor Hermen Overkleeft, PhD , Professor Stan van Boeckel, PhD and their co-workers at the Leiden Institute of Chemistry, Leiden University.
Azafaros’ proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today.
In conjunction with this Series A financing, Azafaros’ board of directors now includes:– Carlo Incerti, MD, Forbion Operating Partner, Chairman and Non-Executive Board Member– Vanessa King, PhD, independent Non-Executive Board Member– Olivier Morand, PhD, Chief Executive Officer and Executive Board Member– Sander Slootweg, MSc, Forbion Managing Partner, Non-Executive Board Member– Edward van Wezel, MSc, BGV Managing Partner, Executive Board Member– Andreas Wallnöfer, PhD, MBA, BioMedPartners General Partner, Non-Executive Board Member. | To read full story, visit https://startuparound.com/read/1582066811.031533/Azafaros-Closes-€25M-Series-A-Financing?ref=audio_experience